EE465 Sacubitril/Valsartan Vs Enalapril Use in the Outpatient Facilities Setting in Spain

Heart failure is a highly prevalent pathology that greatly affects the survival and quality of life of patients. Despite sacubitril/valsartan (sac/val) has demonstrated its effectiveness versus enalapril among patients with heart failure with reduced ejection fraction (HFrEF) in the clinical trials, its prescription remains restricted due to being more expensive than other treatment alternatives like the ACE inhibitors. The aim of this study is to evaluate the cost-effectiveness in outpatient settings of sac/val in patients with HFrEF from the perspective of the Spanish Health System.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research